Li Lin is a seasoned professional in venture capital and investment, currently serving as a Partner at iGlobe Partners since January 2014, specializing in early-stage investments in AI/Big Data, Fintech/Insurtech, and healthcare sectors. Li Lin holds various positions, including Board Observer roles at Accession Therapeutics Limited, Streetbees, Five Sigma, and BigObject Inc., as well as being an investor in C2i Genomics, which was acquired by Veracyte in February 2024. Previous experiences include observing and advising at Matterworks and Aliro Quantum, along with a Board Member tenure at hoolah. Li Lin's early career includes a role as a Senior Consultant at Roland Berger Strategy Consultants. Education includes an MBA from INSEAD, an exchange program at The Wharton School, a Master's in Engineering from Nanyang Technological University Singapore, and a Bachelor's in Engineering from the University of Science and Technology of China.
This person is not in any teams
This person is not in any offices